Avicanna Inc., a biopharmaceutical company specializing in plant-derived cannabinoid-based products, has appointed Mr. Nick Hilborn, CPA, CA as the Chief Financial Officer (CFO) with immediate effect. Mr. Hilborn, who previously held the Interim CFO position since September 2025 and Vice President of Finance since July 2024, brings a wealth of experience from his tenure at Telus, EY, and PwC. Avicanna, listed on TSX under AVCN, OTCQX under AVCNF, and FSE under 0NN, is focused on the development, manufacturing, and commercialization of these products.